NASDAQ:ARAY - Accuray Stock Price, Forecast & News

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Accuray Incorporated (NASDAQ:ARAY) released its quarterly earnings data on Tuesday, January, 28th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.19. The medical equipment provider earned $98.83 million during the quarter, compared to analyst estimates of $98.45 million. Accuray had a negative return on equity of 23.59% and a negative net margin of 0.30%. During the same quarter in the previous year, the firm posted ($0.05) EPS. View Accuray's Earnings History.

Accuray is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Accuray.

Accuray issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, January, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $410-420 million, compared to the consensus revenue estimate of $412.77 million.

2 brokerages have issued twelve-month target prices for Accuray's shares. Their forecasts range from $4.00 to $9.50. On average, they anticipate Accuray's share price to reach $6.75 in the next year. This suggests a possible upside of 119.9% from the stock's current price. View Analyst Price Targets for Accuray.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Accuray.

Media coverage about ARAY stock has trended positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Accuray earned a coverage optimism score of 2.2 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Accuray.

Accuray saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 2,730,000 shares, an increase of 29.4% from the January 30th total of 2,110,000 shares. Based on an average daily volume of 646,800 shares, the days-to-cover ratio is presently 4.2 days. Currently, 3.2% of the shares of the company are sold short. View Accuray's Current Options Chain.

Some companies that are related to Accuray include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Intel (INTC), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Tesla (TSLA), Abeona Therapeutics (ABEO) and Aduro BioTech (ADRO).

Accuray's stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.45%), Archon Capital Management LLC (4.82%), Heartland Advisors Inc. (3.88%), Russell Investments Group Ltd. (3.87%), Royce & Associates LP (2.31%) and State Street Corp (1.80%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Kevin Waters, Patrick Spine and Shigeyuki Hamamatsu. View Institutional Ownership Trends for Accuray.

ARAY stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Mackay Shields LLC, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Oxford Asset Management LLP, State Street Corp, Bank of New York Mellon Corp and Algert Global LLC. Company insiders that have sold Accuray company stock in the last year include Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Patrick Spine and Shigeyuki Hamamatsu. View Insider Buying and Selling for Accuray.

ARAY stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Assenagon Asset Management S.A., Lapides Asset Management LLC, Royce & Associates LP, Barrow Hanley Mewhinney & Strauss LLC, California Public Employees Retirement System, Archon Capital Management LLC and Boston Partners. Company insiders that have bought Accuray stock in the last two years include Joseph E Whitters and Joshua Levine. View Insider Buying and Selling for Accuray.

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARAY stock can currently be purchased for approximately $3.07.

Accuray has a market capitalization of $277.74 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.View Additional Information About Accuray.

The official website for Accuray is http://www.accuray.com/.

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at investors.accuray.com.